We are proud to announce that our U.S. patent US 12,268,712B2 has officially been granted. This milestone recognizes our innovation and dedication in the field of women’s health and specifically postnatal regeneration. The newly granted patent strengthens our intellectual property portfolio and supports the continued development of our flagship product Mommytoo. It also opens new opportunities for partnerships and global expansion. We thank our talented team and collaborators for their relentless efforts in making this achievement possible.

Our abstract entitled “Improving Vaginal Health With a Zinc-Containing Vaginal Hydrogel: A Prospective Cohort Study” has been selected as a Moderated E-Poster/Scientific Salon Presentation at the IUGA/EUGA Joint Meeting 2025.

Join us on June 18-21, 2025 in Barcelona: www.iugaeuga2025.org.

In a paper, published in Gels (an MDPI journal), we have showed JUVIAGEL’s role as an effective, nonhormonal, drug-free, and local adjunct treatment for a variety of vulvovaginal symptoms. The article is available as an Open Access at https://www.mdpi.com/2310-2861/11/3/214

In a paper, published in Gels (an MDPI journal), we have assessed the bioavailability of an estriol-containing vaginal hydrogel. The results suggest the potential of JUVIAGEL in combination with E3 as a biocompatible and effective alternative for the treatment of GSM. The article is available as an Open Access at https://www.mdpi.com/2310-2861/10/12/823

In a paper, published in Science Translational Medicine, we have showed that JUVIAGEL could be effective against recurrent yeast infections. More in our Press Release.

Fempharma has a successful exhibition at CPhI Barcelona 2023.

Fempharma has been successfully audited for ISO 13485:2016 Manufacturing and Trade of Medical Devices by Tequa-Zert, a TÜV Hessen partner.

We have presented our latest study “A randomized controlled pilot trial to assess the effectiveness of a specially formulated food supplement and pelvic floor muscle training in women with stress-predominant urinary incontinence.” at the International Urogynecological Association’s (IUGA) 48th Annual Meeting on June 24, 2023 in The Hague, The Netherlands.

You can find our abstract at URO TODAY Magazine.

Our latest study about the efficacy of INCOXIL has been published at the BMC Women’s Health titled “A randomized controlled pilot trial to assess the effectiveness of a specially formulated food supplement and pelvic floor muscle training in women with stress-predominant urinary incontinence”. It is open access by clicking here.

We have presented our latest study “A randomized controlled trial to assess the effectiveness of a specially formulated food supplement and pelvic floor muscle training in women with stress-predominant urinary incontinence” at the American College of Obstetricians and Gynecologists (ACOG) 2023 Annual Clinical & Scientific Meeting in Baltimore, MD.

You can find our abstract at Obstetrics & Gynecology (the Green Journal)

New clinical trial for Juvia has started. Vaginitis is one of the most common gynecological problems in women. Candida albicans is responsible for more than 85% of vaginal fungal infections and reinfection after standard treatment is quite common. The aim of this study is to compare the effects of Juvia vaginal gel and oral fluconazole on the treatment and recurrence of vulvovaginal candidiasis (VVC). Our hypothesis is that Juvia vaginal gel may decrease the rate of reinfection after standard treatment with oral 150 mg fluconazole.

Fempharma’s proprietary vaginal moisturizer gel JUVIA has gotten into the shelves at Rossmann Hungary.

Fempharma has been successfully audited for ISO 22000:2018 research and development, contract manufacturing of dietary supplements.